CIK-CAR immunotherapy - Formula Pharmaceuticals

Drug Profile

CIK-CAR immunotherapy - Formula Pharmaceuticals

Alternative Names: C.I.K.-CAR.CD19

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Milan Bicocca
  • Developer Fondazione Matilde Tettamanti; Formula Pharmaceutical
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action CD19 antigen inhibitors; Cytokine induced killer cell stimulants; Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Sep 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In children, In adults) in Italy (Parenteral)
  • 11 May 2015 Preclinical trials in Non-Hodgkin's lymphoma in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top